(E)-3-(3,4-dimethoxyphenyl)-1-(2-hydroxy-6-methoxyphenyl)prop-2-en-1-one | 93878-59-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-3-(3,4-dimethoxyphenyl)-1-(2-hydroxy-6-methoxyphenyl)prop-2-en-1-one
• 英文别名: 2'-Hydroxy-3,4,6'-trimethoxychalcone
• CAS: 93878-59-2
• 化学式: C₁₈H₁₈O₅
• 分子量: 314.338
• InChiKey: OJJKWXZJVTZRAR-VQHVLOKHSA-N

物化性质

• 熔点：
  132-133 °C
• 沸点：
  520.1±50.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-3-(3,4-dimethoxyphenyl)-1-(2-hydroxy-6-methoxyphenyl)prop-2-en-1-one 在 sodium carbonate 、 双氧水 作用下， 以 甲醇 、 水 为溶剂， 反应 24.5h， 以47%的产率得到2-(3,4-dimethoxyphenyl)-3-hydroxy-5-methoxy-4H-chromen-4-one
  参考文献：
  名称：

  通过Algar-Flynn-Oyamada（AFO）反应合成5-取代的黄酮醇：机理上的意义

  摘要：

  本文中，我们报告了一种合成方法，该方法通过使用碳酸钠/过氧化氢，通过Algar-Flynn-Oyamada反应（AFO）对5-取代的黄酮醇进行了改进，具有中等至高收率的一系列5-取代的黄酮醇。阐明了AFO反应的机理。LCMS分析和原位1 H NMR分析表明，在碱性碱/过氧化物条件下，环氧化物参与了从查尔酮到黄酮醇和/或金酮的转化。

  DOI：

  10.1016/j.tet.2017.06.064
• 作为产物：
  描述：

  2,6-二羟基苯乙酮 在 potassium hydroxide 、 碘甲烷 作用下， 以 乙醇 、 水 、 丙酮 为溶剂， 反应 24.0h， 生成 (E)-3-(3,4-dimethoxyphenyl)-1-(2-hydroxy-6-methoxyphenyl)prop-2-en-1-one
  参考文献：
  名称：

  Chalcones和Aurones作为选择性MAO-B抑制剂的合成，生物学评估和分子模拟

  摘要：

  合成了一系列查耳酮和金酮，并在体外作为单胺氧化酶抑制剂（MAOi）进行了评估。我们的结果表明，以前未被报道为MAOi的金环是MAO-B抑制剂。因此，两个家族选择性地抑制了微摩尔范围内的MAO的B同工型，为设计新型和有效的MAO抑制剂提供了新颖的支架。借助3D-QSAR和对接研究来表征其活动的主要结构要求。

  DOI：

  10.1111/cbdd.12458

文献信息

• Synthesis, Biological Evaluation, and Molecular Simulation of Chalcones and Aurones as Selective MAO-B Inhibitors
  作者：Nicole Morales-Camilo、Cristian O. Salas、Claudia Sanhueza、Christian Espinosa-Bustos、Silvia Sepúlveda-Boza、Miguel Reyes-Parada、Fernando Gonzalez-Nilo、Marcos Caroli-Rezende、Angélica Fierro

  DOI：10.1111/cbdd.12458

  日期：2015.6

  chalcones and aurones were synthesized and evaluated in vitro as monoamine oxidase inhibitors (MAOi). Our results show that aurones, which had not been previously reported as MAOi, are MAO‐B inhibitors. Thus, both families inhibited selectively the B isoform of MAO in the micromolar range, offering novel scaffolds for the design of new and potent MAO inhibitors. The main structural requirements for their

  合成了一系列查耳酮和金酮，并在体外作为单胺氧化酶抑制剂（MAOi）进行了评估。我们的结果表明，以前未被报道为MAOi的金环是MAO-B抑制剂。因此，两个家族选择性地抑制了微摩尔范围内的MAO的B同工型，为设计新型和有效的MAO抑制剂提供了新颖的支架。借助3D-QSAR和对接研究来表征其活动的主要结构要求。
• Potentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel Hydroxypyrazolines
  作者：Jinhong Park、Poonam Khloya、Yohan Seo、Satish Kumar、Ho K. Lee、Dong-Kyu Jeon、Sungwoo Jo、Pawan K. Sharma、Wan Namkung

  DOI：10.1371/journal.pone.0149131

  日期：——

  The most common mutation of CFTR, affecting approximately 90% of CF patients, is a deletion of phenylalanine at position 508 (F508del, ΔF508). Misfolding of ΔF508-CFTR impairs both its trafficking to the plasma membrane and its chloride channel activity. To identify small molecules that can restore channel activity of ΔF508-CFTR, we synthesized and evaluated eighteen novel hydroxypyrazoline analogues as CFTR potentiators. To elucidate potentiation activities of hydroxypyrazolines for ΔF508-CFTR, CFTR activity was measured using a halide-sensitive YFP assay, Ussing chamber assay and patch-clamp technique. Compounds 7p, 7q and 7r exhibited excellent potentiation with EC50 value <10 μM. Among the compounds, 7q (a novel CFTR potentiator, CP7q) showed the highest potentiation activity with EC50 values of 0.88 ± 0.11 and 4.45 ± 0.31 μM for wild-type and ΔF508-CFTR, respectively. In addition, CP7q significantly potentiated chloride conductance of G551D-CFTR, a CFTR gating mutant; its maximal potentiation activity was 1.9 fold higher than the well-known CFTR potentiator genistein. Combination treatment with CP7q and VX-809, a corrector of ΔF508-CFTR, significantly enhanced functional rescue of ΔF508-CFTR compared with VX-809 alone. CP7q did not alter the cytosolic cAMP level and showed no cytotoxicity at the concentration showing maximum efficacy. The hydroxypyrazolines may be potential development candidates for drug therapy of cystic fibrosis.

  CFTR 最常见的突变是 508 位苯丙氨酸缺失（F508del、ΔF508），约影响 90% 的 CF 患者。 ΔF508-CFTR 的错误折叠会损害其向质膜的运输及其氯通道活性。为了鉴定可以恢复 ΔF508-CFTR 通道活性的小分子，我们合成并评估了 18 种新型羟基吡唑啉类似物作为 CFTR 增强剂。为了阐明羟基吡唑啉对 ΔF508-CFTR 的增强活性，使用卤化物敏感的 YFP 测定、尤斯室测定和膜片钳技术测量 CFTR 活性。化合物 7p、7q 和 7r 表现出优异的增强作用，EC50 值 <10 μM。在这些化合物中，7q（一种新型 CFTR 增强剂，CP7q）显示出最高的增强活性，野生型和 ΔF508-CFTR 的 EC50 值分别为 0.88 ± 0.11 和 4.45 ± 0.31 μM。此外，CP7q 显着增强了 G551D-CFTR（一种 CFTR 门控突变体）的氯电导；其最大增强活性比著名的CFTR增强剂金雀异黄素高1.9倍。与单独使用 VX-809 相比，CP7q 和 VX-809（ΔF508-CFTR 的校正剂）的联合治疗显着增强了 ΔF508-CFTR 的功能挽救。 CP7q 不会改变胞质 cAMP 水平，并且在显示最大功效的浓度下没有表现出细胞毒性。羟基吡唑啉类药物可能是囊性纤维化药物治疗的潜在开发候选者。
• COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING SWEET TASTE
  申请人：Chromocell Corporation

  公开号：US20150050410A1

  公开（公告）日：2015-02-19

  The present invention provides edible compositions comprising a sweet taste modulator of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of sugar in a food product, methods of reducing the caloric intake in a diet, and methods of enhancing sweet taste in a food product.

  本发明提供了包含本发明的甜味调节剂的可食用组合物、包含这种可食用组合物的食品产品以及制备这种食品产品的方法。本发明还提供了减少食品产品中糖分量的方法、减少饮食中热量摄入的方法以及增强食品产品甜味的方法。
• Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors
  作者：Václav Zima、Kateřina Radilová、Milan Kožíšek、Carlos Berenguer Albiñana、Elena Karlukova、Jiří Brynda、Jindřich Fanfrlík、Miroslav Flieger、Jan Hodek、Jan Weber、Pavel Majer、Jan Konvalinka、Aleš Machara

  DOI：10.1016/j.ejmech.2020.112754

  日期：2020.12

  The biological effects of flavonoids on mammal cells are diverse, ranging from scavenging free radicals and anti-cancer activity to anti-influenza activity. Despite appreciable effort to understand the anti-influenza activity of flavonoids, there is no clear consensus about their precise mode-of-action at a cellular level. Here, we report the development and validation of a screening assay based on AlphaScreen technology and illustrate its application for determination of the inhibitory potency of a large set of polyols against PA N-terminal domain (PA-Nter) of influenza RNA-dependent RNA polymerase featuring endonuclease activity. The most potent inhibitors we identified were luteolin with an IC₅₀ of 72 ± 2 nM and its 8-C-glucoside orientin with an IC₅₀ of 43 ± 2 nM. Submicromolar inhibitors were also evaluated by an in vitro endonuclease activity assay using single-stranded DNA, and the results were in full agreement with data from the competitive AlphaScreen assay. Using X-ray crystallography, we analyzed structures of the PA-Nter in complex with luteolin at 2.0 Å resolution and quambalarine B at 2.5 Å resolution, which clearly revealed the binding pose of these polyols coordinated to two manganese ions in the endonuclease active site. Using two distinct assays along with the structural work, we have presumably identified and characterized the molecular mode-of-action of flavonoids in influenza-infected cells.
• Seshadri; Venkateswarlu, Proceedings - Indian Academy of Sciences, Section A, 1949, vol. 26, p. 195
  作者：Seshadri、Venkateswarlu

  DOI：——

  日期：——